Igm Biosciences, INC

IGM Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $1.247 per share in cash plus a contingent value right, with the transaction expected to close in August 2025.

IGM Biosciences, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum Market Value of Listed Securities requirement, initiating a 180-day period to regain compliance.

IGM Biosciences, Inc. has announced the early termination of its headquarters lease in Mountain View, California, effective May 31, 2025, in exchange for a $14.2 million termination payment and conveyance of certain assets.

IGM Biosciences announced the termination of its collaboration agreement with Sanofi, resulting in a significant workforce reduction and facility closures as the company explores strategic alternatives.

IGM Biosciences amends its previous 8-K filing to provide estimated restructuring charges between $0.7 million and $2.0 million following the halt of imvotamab and IGM-2644 development for autoimmune diseases.

IGM Biosciences announces a strategic shift, discontinuing development of imvotamab and IGM-2644 for autoimmune diseases and reducing its workforce by 73% to preserve cash.

IGM Biosciences announced a significant net income for Q2 2025 driven by the termination of its Sanofi collaboration agreement, while confirming a pending merger with Concentra Biosciences and substantial operational wind-down.

IGM Biosciences announces Q1 2025 financial results, a strategic shift involving halted development programs and workforce reductions, and the termination of its collaboration agreement with Sanofi.

IGM Biosciences reports a strategic shift to focus on autoimmunity, accompanied by a workforce reduction and pipeline reprioritization in its latest quarterly filing.

IGM Biosciences' second quarter 2024 results show a net loss of $47.9 million, with a strategic refocusing on immunology targets and the termination of oncology collaborations with Sanofi.

IGM Biosciences announced its first quarter 2024 financial results, highlighting a strategic shift to focus exclusively on immunology targets in its collaboration with Sanofi.

IGM Biosciences files an amendment to its annual report to provide additional details on its board of directors, executive compensation, and corporate governance practices.

IGM Biosciences pivots to autoimmunity, reports significant losses, and outlines strategic alternatives in its latest 10-K filing.

IGM Biosciences updates its employee stock purchase plan and formalizes its outside director compensation policy, detailing cash retainers, equity grants, and clawback provisions.

Baker Bros. Advisors LP and related entities report the disposition of all their shares in IGM Biosciences, Inc. following its acquisition by Concentra Biosciences, LLC.

IGM Biosciences, Inc. completed its merger with Concentra Biosciences, LLC, resulting in Redmile Group, LLC disposing of all its equity and warrant holdings.

IGM Biosciences Director Julie Hambleton reports the disposition of all common stock holdings following the company's merger into a wholly-owned subsidiary of Concentra Biosciences.

IGM Biosciences director Michael Lee reported the sale of 12,712 common shares following the company's merger with Concentra Biosciences, receiving $1.247 cash and a CVR per share.

Topsoe Holding A/S reports the disposition of its entire stake in IGM Biosciences, Inc. following the company's merger into a wholly-owned subsidiary of Concentra Biosciences, LLC.

IGM Biosciences, Inc. completed its merger with Concentra Biosciences, converting all outstanding shares into cash and contingent value rights.

IGM Biosciences announces its 2024 Annual Meeting to be held on June 11, 2024, with key proposals including the election of directors, ratification of the accounting firm, liability limitations for officers, and a stock option exchange program.

IGM Biosciences announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, featuring proposals for director elections, auditor ratification, officer liability limitation, and a stock option exchange program.

Baker Bros. Advisors LP and affiliates report full disposition of IGM Biosciences shares following the company's merger with Concentra Biosciences.

Topsoe Holding A/S and related individuals have ceased to beneficially own 5% or more of IGM Biosciences, Inc. common stock following a merger agreement with Concentra Biosciences, LLC.

Redmile Group, LLC reports the disposition of its entire stake in IGM Biosciences, Inc. following the completion of the company's acquisition by Concentra Biosciences, LLC.

Glazer Capital, LLC and Paul J. Glazer report a complete divestment of their beneficial ownership in IGM Biosciences, Inc. as of September 30, 2025.

Glazer Capital, LLC and its managing member, Paul J. Glazer, have disclosed a passive beneficial ownership of 7.3% in IGM Biosciences, Inc.'s common stock.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 10.5% beneficial ownership stake in IGM Biosciences Inc. as of December 31, 2024.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.2% in IGM Biosciences Inc.'s common stock as of January 31, 2025.